Literature DB >> 30144377

Validity of Japanese version of SARC-F questionnaire in patients with chronic liver disease.

Satoshi Ida1, Yuji Kojima2, Shima Hamaoka2, Naohito Urawa2, Jun Araki2, Ryutaro Kaneko1, Kazuya Murata1.   

Abstract

BACKGROUND AND AIM: We aimed to examine the validity of the Japanese version of SARC-F questionnaire (SARC-F-J) that employs the diagnostic criteria for sarcopenia established by the Japan Society of Hepatology in patients with chronic liver disease.
METHODS: Subjects were outpatients at the Department of Hepatology at the Japanese Red Cross Ise Hospital, Japan. Evaluations were performed using the following self-administered questionnaires: SARC-F-J, Tokyo Metropolitan Institute of Gerontology Index of Competence (TMIG-IC), the Japanese version of the Falls Efficacy Scale (FES), and Kaigo-Yobo Checklist (CL). Based on the diagnostic criteria of the Japan Society of Hepatology, we diagnosed sarcopenia from the skeletal muscle index calculated using the iliopsoas muscle area at the third lumbar vertebra on computed tomography and from grip strength. To evaluate construct validity, we calculated the sensitivity, specificity, and positive and negative predictive values of SARC-F-J that used the diagnostic criteria of the Japan Society of Hepatology as reference. Furthermore, to evaluate convergent validity, we calculated Pearson's correlation coefficients between SARC-F-J and TMIG-IC, FES, and CL.
RESULTS: A total of 140 subjects were included in the analysis set. Sensitivity and specificity were 16.3% and 45.0% and 95.3% and 90.8% for men and women, respectively. The positive predictive value was 81.8% for both, whereas the negative predictive value was 47.1% and 64.5% for men and women, respectively. A significant correlation was seen between SARC-F-J and TMIG-IC, FES, and CL.
CONCLUSIONS: We believe that the SARC-F-J is a valid tool for patients with chronic liver disease.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  liver disease; sarcopenia; screening

Mesh:

Year:  2018        PMID: 30144377     DOI: 10.1111/jgh.14449

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  Editorial: Screening for Sarcopenia.

Authors:  J E Morley; A M Sanford
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease.

Authors:  Tatsuki Ichikawa; Hisamitsu Miyaaki; Satoshi Miuma; Yasuhide Motoyoshi; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Yusuke Nakano; Tetsurou Honda; Hiroyuki Yajima; Ryouhei Uehara; Osamu Miyazaki; Yasutaka Kuribayashi; Keiji Kira; Naota Taura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2021-02-11

3.  Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer).

Authors:  Johanne Poisson; Claudia Martinez-Tapia; Damien Heitz; Romain Geiss; Gilles Albrand; Claire Falandry; Mathilde Gisselbrecht; Anne-Laure Couderc; Rabia Boulahssass; Evelyne Liuu; Pascaline Boudou-Rouquette; Anne Chah Wakilian; Cedric Gaxatte; Fréderic Pamoukdjian; Laure de Decker; Valery Antoine; Catherine Cattenoz; Heidi Solem-Laviec; Olivier Guillem; Hayat Medjenah; Pierre André Natella; Florence Canouï-Poitrine; Marie Laurent; Elena Paillaud
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-09-14       Impact factor: 12.910

4.  The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome.

Authors:  Takumi Noda; Kentaro Kamiya; Nobuaki Hamazaki; Kohei Nozaki; Takafumi Ichikawa; Masashi Yamashita; Shota Uchida; Emi Maekawa; Tasuku Terada; Jennifer L Reed; Minako Yamaoka-Tojo; Atsuhiko Matsunaga; Junya Ako
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.